Breaking News, Trials & Filings

FDA Accepts Afrezza Submission

MannKind tries again with inhaled insulin

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

The FDA has acknowledged the resubmission of an NDA by MannKind Corp. for Afrezza (insulin human [rDNA origin]) Inhalation Powder. The FDA considered the updated NDA to be a complete class 2 response to its Complete Response Letter issued in January 2011 and assigned a user fee goal date of April 15, 2014....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters